NO945093L - Targeted release of growth factors for bone regeneration - Google Patents

Targeted release of growth factors for bone regeneration

Info

Publication number
NO945093L
NO945093L NO945093A NO945093A NO945093L NO 945093 L NO945093 L NO 945093L NO 945093 A NO945093 A NO 945093A NO 945093 A NO945093 A NO 945093A NO 945093 L NO945093 L NO 945093L
Authority
NO
Norway
Prior art keywords
growth factors
bone regeneration
targeted release
acid
bone
Prior art date
Application number
NO945093A
Other languages
Norwegian (no)
Other versions
NO945093D0 (en
Inventor
Joseph R Garlich
Samuel E Lynch
James R Pribish
Original Assignee
Dow Chemical Co
Inst Molecular Biology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/026,800 external-priority patent/US5505931A/en
Priority claimed from PCT/US1993/006254 external-priority patent/WO1994000145A1/en
Application filed by Dow Chemical Co, Inst Molecular Biology Inc filed Critical Dow Chemical Co
Publication of NO945093D0 publication Critical patent/NO945093D0/en
Publication of NO945093L publication Critical patent/NO945093L/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives systemer for målrettet avgivelse av spesifikke blandinger, hvor vekstfaktorer er koblet, eventuelt ved bruk av et syrespaltbart sammenkoblende ledd, til en polyaminometylenfosfonsyreligand, og som er særlig egnet for målrettet avgivelse til ben. Når det syrespaltbare sammen- koblende ledd er tilstede, aktiveres blandingen for vekst- faktorene på det aktuelle bensetet, mens det forblir inaktivt i kroppens kretsløp. En fremgangsmåte for fremstilling av forbindelsen og blandingen er også beskrevet.There are disclosed systems for targeted delivery of specific compositions, wherein growth factors are coupled, optionally by the use of an acid-cleavable linking link, to a polyaminomethylene phosphonic acid ligand, and which is particularly suitable for targeted delivery to bone. When the acid-cleavable linking link is present, the mixture is activated for the growth factors of the particular bone, while remaining inactive in the body's circulation. A process for the preparation of the compound and mixture is also described.

NO945093A 1992-06-30 1994-12-30 Targeted release of growth factors for bone regeneration NO945093L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90698092A 1992-06-30 1992-06-30
US08/026,800 US5505931A (en) 1993-03-04 1993-03-04 Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
PCT/US1993/006254 WO1994000145A1 (en) 1992-06-30 1993-06-30 Targeted delivery of growth factors for bone regeneration

Publications (2)

Publication Number Publication Date
NO945093D0 NO945093D0 (en) 1994-12-30
NO945093L true NO945093L (en) 1995-02-27

Family

ID=27362848

Family Applications (1)

Application Number Title Priority Date Filing Date
NO945093A NO945093L (en) 1992-06-30 1994-12-30 Targeted release of growth factors for bone regeneration

Country Status (1)

Country Link
NO (1) NO945093L (en)

Also Published As

Publication number Publication date
NO945093D0 (en) 1994-12-30

Similar Documents

Publication Publication Date Title
GEP20012578B (en) (54) Heteroaryl Succinamides, Pharmaceutical Compositions Containing the Same and Methods for Treatment of the Diseases Caused by Metalloproteinase Activity
ATE231519T1 (en) DINUCLEOTIDES FOR USE IN THE TREATMENT OF LUNG DISEASES
CA2229077A1 (en) Lipid metabolism improving agent
DE69727956D1 (en) PHARMACEUTICAL PREPARATIONS FOR REDUCING BREATHING DEPRESSIONS
DE69310602D1 (en) 3 ', 5'-Ditertbutyl-4'-hydroxyflavone, process for their preparation and pharmaceutical composition with antioxidant and antivasoconstriction activity
AU550391B2 (en) Derivatives of c-076 compounds
MX9503529A (en) Glycinamide derivatives, process for their preparation and medicaments containing them.
ID28160A (en) TREATMENT SYSTEM FOR THE PROVISION OF PHENILASETYLGLUTAMINA, PHENILASETYLISOGLUTAMINA AND / OR PHENILASETATE.
EP2308496A3 (en) Formulation containing phosphate derivatives of electron transfer agents
WO1997048369A3 (en) Prophylactic and therapeutic treatment of skin sensitization and irritation
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
Lange Inhibiting effect of tobacco smoke on some crystalline enzymes
MY115466A (en) Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents and medicaments comprising them.
ES2105923B1 (en) COMPOSITIONS FOR THE TREATMENT OF AN INFECTION AND DISEASE CAUSED BY THE HEPATITIS B (HBV) VIRUS.
MY118244A (en) Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
NO945093L (en) Targeted release of growth factors for bone regeneration
Zieve et al. Ammonia, octanoate and a mercaptan depress regeneration of normal rat liver after partial hepatectomy
ATE181829T1 (en) GABA-ERGIC MODULATION OF EYE GROWTH
WO1990003172A3 (en) Bile acids for treatment of viral infections
HUT54113A (en) Process for producing butenecarboxylic acid derivatives and pharmaceutical compositions comprising such compounds
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
DE59610819D1 (en) MEDICINAL PRODUCTS FOR SELECTIVELY FIGHTING TUMOR TISSUE
CA2385301A1 (en) Peeling composition
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal